Assimakis Komninos

White & Case (Brussels)
Lawyer (Partner)

Dr Assimakis Komninos is a Partner at the Brussels office of White & Case. Between 2009 and 2011 he was a Commissioner and Member of the Board of the Hellenic Competition Commission (HCC). He has acted before the European Court of Justice in Syfait v. GlaxoSmithKline and Lélos v. GlaxoSmithKline (parallel trade of pharmaceuticals - abuse of dominance), and in GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - Article 101). He was also involved before the EU General Court in Microsoft v. Commission (compulsory licensing of interoperability information), GlaxoSmithKline Services v. Commission (parallel trade of pharmaceuticals - application of Article 101), Chalkor Metal Works v. Commission (copper plumbing tubes) and Public Power Corporation v. Commission (Greek lignites). Dr Komninos successfully represented Aegean Airlines as lead counsel in Aegean/Olympic II, which resulted in the European Commission clearing the deal two years after it had previously blocked it. He has also represented or advised clients in proceedings before the Albanian, Cypriot, French, Greek, Kosovo and Romanian competition authorities and Belgian, Bulgarian, Cypriot, French, Greek, Latvian and Spanish appellate courts, and has particular expertise in arbitration cases involving EU and national competition issues, and in private antitrust litigation cases in national courts. Dr Komninos is currently a visiting fellow of the Centre for Law and Governance in Europe at University College London (UCL), where he teaches EU competition law, and a senior associate fellow of the Institute for European Studies (IES) at the Vrije Universiteit Brussels (VUB).

Distinctions

Linked authors

General Court of the European Union (Luxembourg)
Institut d’économie Industrielle (IDEI)
European Commission (Brussels)
Garrigues (Brussels)
University of Strasbourg
University College London
RBB Economics (Brussels)

Videos

Assimakis Komninos
Assimakis Komninos 28 October 2016 New York
Assimakis Komninos & Jacquelyn Maclennan, White & Case
Assimakis Komninos 25 March 2014 Washington DC

Articles

17379 Bulletin

James Killick, Assimakis Komninos, Aqeel Kadri The UK Court of Appeal upholds the Competition Appeal Tribunal’s quashing of the Competition Autority’s decision against pharmaceutical undertakings who had abused their dominant position by pricing their epilepsy drug unfairly (Pfizer / Flynn Pharma)

82

On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal’s (CAT) quashing of the Competition and Markets Authority’s (CMA) decision that Pfizer and Flynn Pharma (Flynn) had abused their dominant positions in the market by pricing their epilepsy drug unfairly. Among other (...)

James Killick, Assimakis Komninos, Strati Sakellariou-Witt, Axel P. Schulz The UK Competition Authority closes its investigation into an allegedly abusive discount scheme in the pharmaceutical sector (Remicade)

431

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The CMA Remicade decision: discount schemes and abuse of dominance – effects matter!* Summary On 14 March 2019, the UK Competition and Markets Authority (CMA) (...)

Assimakis Komninos, James Killick The EU Court of Justice dismisses the Commission’s appeal against the annulment of its decision to prohibit a merger in the parcel delivery market (UPS / TNT)

528

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. EU Court confirms the need for transparency and full disclosure of economic analyses in EU merger cases (UPS/TNT)* On 16 January 2019, the Court of Justice of (...)

Assimakis Komninos, James Killick The UK Competition Appeal Tribunal announces its provisional judgment in an appeal against the Competition Authority’s infringement decision in an excessive price case (Pfizer / Flynn)

425

I. Introduction In the last couple of years, there has been a trend for antitrust watchdogs around the world to investigate excessive pricing, especially in the phar- maceutical sector. Last year, the European Commission opened its first investigation into excessive pricing in the (...)

Assimakis Komninos, Jacquelyn MacLennan, James Killick, Jan Jeram, Jérémie Jourdan, Strati Sakellariou-Witt The EU Court of Justice endorses an effects-based assessment of rebates (Intel)

630

This article has been nominated for the 2018 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On 6 September 2017, the Court of Justice of the European Union ("CJEU" or "Court") essentially held in Intel that the European Commission ("Commission") cannot (...)

Assimakis Komninos, Ian Forrester, James Killick The EU Court of Justice holds that parent companies may be fined for repeated infringements even without being an addressee of the earlier decisions (Versalis)

736

On 5 March 2015, the European Court of Justice (CoJ) handed down its judgment in Versalis , concerning the increasing of fines for antitrust infringements where a company is found to be a repeat offender. The judgment raises important questions about the respect for the rights of defence in EU (...)

Assimakis Komninos, Ian Forrester, Jacquelyn MacLennan, Kai Struckmann, Mark D. Powell, Pontus Lindfelt The European Commission adopts a package on private damages actions in antitrust cases

174

This article has been nominated for the 2014 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. Summary On 11 June 2013, the European Commission (“Commission”) adopted a proposal for a directive on how citizens and companies can bring damages claims under EU (...)

Assimakis Komninos The EU Court of Justice rules that the Greek Competition Authority is not a “court or tribunal” in the meaning of Art. 234 EC and therefore can not apply for an ECJ preliminary ruling (Syfait / GlaxoSmithKline)

10454

On 31 May 2005 the European Court of Justice (ECJ) delivered its judgment in Case C-53/03, Syfait and others v. GlaxoSmithKline AEVE and GlaxoSmithKline plc (“Syfait”), which raises the question of whether a dominant pharmaceutical undertaking is under a duty to supply unlimited quantities of (...)

32483 Review

Agisilaos Karpetas, Assimakis Komninos, Frédéric Jenny, Knut Fournier, Michèle Carpagnano The recovery of antitrust harms in foreign legal systems (Antitrust damages actions in France and in Europe : Current situation and upcoming changements, Paris, 13 May 2014)

847

The first roundtable of the conference held in Paris, the 13th May 2014 on the recovery of antitrust harm was dedicated to the antitrust harm in foreign legal systems. Michele CARPAGNANO Professor, University of Trento Co-Director, Osservatorio Antitrust Knut PROVIDER Research Associate, (...)

Assimakis Komninos, Florence Ninane, Francesco Rosati, Geoffrey D. Oliver, Hendrik Bourgeois, Ioannis Lianos, James Killick, Johanne Peyre, Niamh McCarthy, Philippe Choné The EU guidance on exclusionary abuses: A step forward or a missed opportunity?

6810

Quelles sont les conséquences pour les entreprises de la Communication de la Commission concernant l’article 82 du Traité ? Rend-elle l’action de la Commission plus prévisible ? L’utilisation de nombreux critères économiques réduit-elle le risque que les pratiques pro-concurrentielles des entreprises (...)

Assimakis Komninos The EU White Paper for damages actions: A first appraisal

6124

La Commission européenne a publié début avril 2008 son Livre blanc sur les actions en dommages et intérêts pour infraction aux règles communautaires sur les ententes et les abus de position dominante. Le Livre blanc présente un certain nombre de propositions spécifiques qui permettront de faciliter en (...)

Assimakis Komninos, Ian Forrester Lisbonne Agenda and Competition Law

5552

The European Commission tends to refer more and more to the Lisbon Agenda in various competition policy documents. The authors are of the opinion that such a tendancy is contrary to the objectives of the competition policy. Recently, in some of its official communications on Community (...)

Books

Send a message